Physician profile
Anna Hung-Chan
NPI 1881064004
$3,868.26
in general payments reported to CMS, 2019-2025
17 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $382 · 2023: $512 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,033.21 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $447.02 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $445.12 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $345.61 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $316.84 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $304.44 | 2025 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $256.18 | 2025 | Auvelity |
| Alkermes, INC. | $191.02 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $172.57 | 2025 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $111.47 | 2022-2025 | |
| Lundbeck LLC | $89.97 | 2025 | Rexulti |
| Indivior INC. | $71.59 | 2023-2025 | Sublocade, Perseris |
| Supernus Pharmaceuticals, INC. | $21.42 | 2025 | Qelbree |
| Neos Therapeutics, LP | $15.81 | 2025 | Exxua |
| Takeda Pharmaceuticals U.S.A., INC. | $15.79 | 2025 | Trintellix |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $15.17 | 2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $15.03 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Hung-Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.